Horizon Pharma offers $300M senior notes and borrows money for buying Raptor Pharmaceuticals
Horizon Pharma, with its wholly owned subsidiaries, Horizon Pharma, Inc. and Horizon Pharma USA, Inc., intends to offer $300 million aggregate principal amount of senior notes due 2024, and to borrow $375 million.